ArticleVeterinary sciences2025
Development and Immunogenicity Study of Subunit Vaccines Based on Spike Proteins of Porcine Epidemic Diarrhea Virus and Porcine Transmissible Gastroenteritis Virus.
Article in Veterinary sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Porcine deltacoronavirus nucleocapsid protein inhibits RIG-I signaling pathway by suppressing G3BP1-mediated stress granules formation.Virulence · 2026Article
- Overcoming Antigenic Drift in PEDV: Broadly Protective Antigen Design and sIgA-Driven Lactogenic Immunity.Veterinary sciences · 2026Review
- TGEV activates RIG-I/IFN-β/STAT1 axis to promote NLRC5-mediated SLA-I upregulation.Veterinary research · 2026Article
- The PCK2-Traf6-Tollip Axis Restricts PEDV Replication by Orchestrating Selective Autophagic Degradation of the Viral Nucleocapsid Protein.Transboundary and emerging diseases · 2026Article
- Genetic Diversity, Recombination, and Pathogenicity of Porcine Epidemic Diarrhea Virus Strains Circulating in China During 2023-2024.Transboundary and emerging diseases · 2026Article
- Development of a ferritin-based subunit nanoparticle vaccine targeting the S-RBD of porcine transmissible gastroenteritis virus.Frontiers in veterinary science · 2026Article
- Engineering a TGEV S-trimer chimera with PEDV D0-NTD generates potent neutralizing antibodies against both viruses.Journal of virology · 2025Article
- How Does Porcine Epidemic Diarrhea Virus Escape Host Innate Immunity?Pathogens (Basel, Switzerland) · 2025Review
- Design of Mucosal Vaccines Against Swine Enteric Coronaviruses: From Antigen Delivery to Immune Activation.Transboundary and emerging diseases · 2025Review
- Next-Generation Vaccines for Co-Circulating PEDV and TGEV: Integrating Nucleic Acid Platforms, Mucosal Delivery, and AI-Driven Antigen Design.Transboundary and emerging diseases · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Porcine epidemic diarrhea virus (PEDV) and transmissible gastroenteritis virus (TGEV) are responsible for significant economic losses in the swine industry. The S1 proteins of these viruses serve as key targets for vaccine development. In this study, prokaryotic expression vectors for pCZN1-PEDV S1, pCZN1-TGEV S1, and pCZN1-PEDV S1-TGEV S1 were constructed. The corresponding proteins were expressed, purified, and used to prepare monovalent, bivalent, and mixed (PEDV S1 + TGEV S1) vaccines. Kunming (KM) mice were immunized with subunit vaccines, with PBS as the negative control (NC) and a commercial inactivated vaccine as the positive control (PC). Immune responses, including specific antibody (IgG, IgG1, IgG2a) levels, virus neutralization, and IFN-γ production, were evaluated. All vaccines induced high levels of specific IgG, IgG1, and IgG2a antibodies. At weeks 2 and 8, the PEDV S1 + TGEV S1 vaccine induced significantly higher levels of specific IgG and IgG1 compared to the PC (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.